We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
Read MoreHide Full Article
Amicus Therapeutics (FOLD - Free Report) announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold (migalastat), which is approved for treating Fabry disease and Pombiliti + Opfolda.
The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.
Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025.
In the past year, shares of Amicus have plunged 31.6% compared with the industry’s decline of 16%.
Image Source: Zacks Investment Research
FOLD's Strategic Goals and Outlook 2025
For full-year 2025, management expects total revenues to grow in the range of 17%-24% on a constant exchange rate (CER).
Revenues from Galafold are expected to grow in the range of 10%-15% at CER in 2025.
The company expects Pombiliti + Opfolda revenue growth of 65%-85% at CER for full-year 2025.
Both Fabry disease and Pompe disease are rare diseases. Amicus is currently advancing ongoing studies to broaden labels in Fabry and Pompe diseases.
Amicus expects to achieve positive GAAP net income in the second half of 2025. The company expects to exceed $1 billion in total sales in 2028.
FOLD Settles Galafold Patent Litigation
In October 2024, Amicus signed a licensing agreement with Teva Pharmaceuticals (TEVA - Free Report) , resolving the patent lawsuit FOLD filed earlier.
The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold 123 mg capsules before the related patents expired.
Per the settlement terms, TEVA will not be able to sell its generic version of Galafold in the United States until January 2037.
The agreement also ended all ongoing litigation between Amicus and Teva concerning Galafold patents in the U.S. District Court for Delaware.
FOLD's Preliminary Results for 2024
Preliminary total revenues were $528.5 million in 2024, reflecting an increase of 32% year over year at CER. Total revenues were $149.9 million in the fourth quarter of 2024.
Preliminary Galafold net revenues were $458.2 million in 2024, reflecting an increase of 18% year over year at CER. Net Galafold revenues were $127.7 million in the fourth quarter of 2024.
Preliminary net product sales from Pombiliti + Opfolda were $70.3 million in 2024. Pombiliti + Opfolda net sales were $22.2 million in the fourth quarter of 2024.
Per management, several pricing and reimbursement agreements related to Pombiliti + Opfolda were achieved in late 2024 and early 2025.
In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have plunged 49.7%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 36%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
Amicus Therapeutics (FOLD - Free Report) announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold (migalastat), which is approved for treating Fabry disease and Pombiliti + Opfolda.
The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.
Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025.
In the past year, shares of Amicus have plunged 31.6% compared with the industry’s decline of 16%.
Image Source: Zacks Investment Research
FOLD's Strategic Goals and Outlook 2025
For full-year 2025, management expects total revenues to grow in the range of 17%-24% on a constant exchange rate (CER).
Revenues from Galafold are expected to grow in the range of 10%-15% at CER in 2025.
The company expects Pombiliti + Opfolda revenue growth of 65%-85% at CER for full-year 2025.
Both Fabry disease and Pompe disease are rare diseases. Amicus is currently advancing ongoing studies to broaden labels in Fabry and Pompe diseases.
Amicus expects to achieve positive GAAP net income in the second half of 2025. The company expects to exceed $1 billion in total sales in 2028.
FOLD Settles Galafold Patent Litigation
In October 2024, Amicus signed a licensing agreement with Teva Pharmaceuticals (TEVA - Free Report) , resolving the patent lawsuit FOLD filed earlier.
The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of Amicus' Galafold 123 mg capsules before the related patents expired.
Per the settlement terms, TEVA will not be able to sell its generic version of Galafold in the United States until January 2037.
The agreement also ended all ongoing litigation between Amicus and Teva concerning Galafold patents in the U.S. District Court for Delaware.
FOLD's Preliminary Results for 2024
Preliminary total revenues were $528.5 million in 2024, reflecting an increase of 32% year over year at CER. Total revenues were $149.9 million in the fourth quarter of 2024.
Preliminary Galafold net revenues were $458.2 million in 2024, reflecting an increase of 18% year over year at CER. Net Galafold revenues were $127.7 million in the fourth quarter of 2024.
Preliminary net product sales from Pombiliti + Opfolda were $70.3 million in 2024. Pombiliti + Opfolda net sales were $22.2 million in the fourth quarter of 2024.
Per management, several pricing and reimbursement agreements related to Pombiliti + Opfolda were achieved in late 2024 and early 2025.
FOLD's Zacks Rank & Stocks to Consider
Amicus currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech sector are CytomX Therapeutics, Inc. (CTMX - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have plunged 49.7%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 36%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.